Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Obstructive Pulmonary Disorder Clear all
Completed Phase 2 Interventional

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01867762
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
JNJ 49095397, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • St Louis, Missouri • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 26, 2026, 7:31 PM EDT
Recruiting No phase listed Observational

STRIVE Post-Market Registry Study

NCT04302272
View directory record Official record
Conditions
Emphysema
Interventions
Spiration Valve System (SVS)
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Phoenix, Arizona • Mountain View, California • Coral Gables, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

NCT03622112
View directory record Official record
Conditions
Asthma
Interventions
AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
21
States / cities
Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation

NCT01799330
View directory record Official record
Conditions
COPD
Interventions
Transcutaneous Electrical Muscle Stimulation (TCEMS), Sham TCEMS
Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 26, 2026, 7:31 PM EDT
Terminated Phase 3 Interventional

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

NCT04636801
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
4,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Sheffield, Alabama • Northridge, California • Cutler Bay, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 26, 2026, 7:31 PM EDT
Withdrawn Phase 2 Interventional

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

NCT00323024
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
NX1011
Drug
Lead sponsor
NITROX, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2007 · Synced Sep 26, 2026, 7:31 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Symbicort on the Ventilatory Kinematics

NCT01712854
View directory record Official record
Conditions
Chronic Obstructive Lung Disease
Interventions
Budesonide, Symbicort
Drug
Lead sponsor
Columbia University
Other
Eligibility
40 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional Results available

Family-supported Smoking Cessation for Chronically Ill Veterans

NCT00448344
View directory record Official record
Conditions
Chronic Disease, Neoplasm, Cardiovascular Disease, Pulmonary Disease, Chronic Obstructive, Diabetes Mellitus, Hypertension
Interventions
Family-supported, Standard Telephone counseling
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 26, 2026, 7:31 PM EDT
Suspended Phase 1 Interventional

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT05993611
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD

NCT03534934
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Osteoporosis
Interventions
Vital signs, Urine Pregnancy Test, Questionnaires, Blood Test, Duel-energy X-ray absorptiometry scan, Multi-detector computed tomography, Dual-energy X-ray absorptiometry scan
Diagnostic Test · Other
Lead sponsor
Punam K Saha
Other
Eligibility
45 Years to 90 Years
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Iowa City, Iowa • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Early Phase 1 Interventional

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

NCT04298606
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Recruiting Not applicable Interventional

A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain

NCT07214844
View directory record Official record
Conditions
Low Back Pain, Chronic
Interventions
Iovera Medial Branch Cryoneurolysis, Radiofrequency ablation (RFA)
Device · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Not yet recruiting Not applicable Interventional

Developing an Intervention to Optimize Virtual Care Adoption for COPD Management

NCT05986214
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
VC-OPTIONS
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Bedford, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 3 Interventional

Study in Patients With COPD

NCT00215449
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
68
States / cities
Bessemer, Alabama • Birmingham, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316900
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444, tiotropium bromide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

NCT03324607
View directory record Official record
Conditions
COPD
Interventions
hyperpolarized 129Xe gas MRI, Bevespi Aerosphere
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

NCT06075095
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Oral Dexamethasone Doses in Asthma Exacerbation

NCT00942201
View directory record Official record
Conditions
Asthma, Reactive Airway Disease
Interventions
Dexamethasone
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
2 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2009 · Synced Sep 26, 2026, 7:31 PM EDT
Not yet recruiting Not applicable Interventional

Respiratory Oxygen Adherence Monitor for Chronic Obstructive Pulmonary Disease Patients

NCT06874101
View directory record Official record
Conditions
COPD, COPD - Chronic Obstructive Pulmonary Disease
Interventions
Activated ROAM System with User Feedback, Sham Comparator
Device
Lead sponsor
Barron Associates, Inc.
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 26, 2026, 7:31 PM EDT
Not listed Not applicable Interventional

Inspiratory Muscle Training in COPD

NCT03438019
View directory record Official record
Conditions
COPD
Interventions
PrO2, Threshold Inspiratory Muscle Trainer
Device
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Chronic Obstructive Pulmonary Disease

NCT00104637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
sildenafil citrate, Placebo
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 26, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 26, 2026, 7:31 PM EDT